Compare DexCom, Inc. (DXCM) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Teladoc Health Inc — how do they compare? DexCom, Inc. trades at $83.72 (market cap $31.86B), while Teladoc Health Inc trades at $5.62 (market cap $1.01B). The key difference: DexCom, Inc. is far larger — about 31.5× Teladoc Health Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Teladoc Health Inc for 39 Days on average.
| DXCM | TDOC | |
|---|---|---|
Market Cap | $31.86B | $1.01B |
Volume | 3,607,070 | 4,668,477 |
Sector | Health | Health |
52-Week High | $92.34 | $9.72 |
52-Week Low | $54.84 | $4.47 |
Typical Hold Time | 62 Days | 39 Days |
Enterprise Value | $31.32B | $1.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Teladoc Health (TDOC) trades at $5.56, down 3.64% on the day, reflecting persistent bearish technical signals and negative earnings. The stock shows weak profitability with a net income margin of -7.13% and negative ROE, though valuation ratios like P/S of 0.4 and EV/EBITDA of 5.89 appear low. Recent news includes a CFO transition and ongoing investor investigations, adding to uncertainty.
The outlook remains challenging due to consecutive net losses and competitive pressures, but the consensus price target of $8.83 suggests potential upside if operational improvements materialize. Key risks include sustained unprofitability, high debt levels, and weak sentiment, requiring careful monitoring of cost management and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
